Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: A single institution experience Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Large Cell
  • Lung Neoplasms
  • Neuroendocrine Tumors

abstract

  • The LCNEC has a high response rate to platinum-based neoadjuvant chemotherapy. Resected advanced-stage patients receiving combination neoadjuvant and (or) adjuvant chemotherapy may have a survival advantage. These therapies should be considered in resectable patients with LCNEC.

publication date

  • October 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.athoracsur.2011.05.027

PubMed ID

  • 21867986

Additional Document Info

start page

  • 1180

end page

  • 6; discussion 1186-7

volume

  • 92

number

  • 4